Case reportPublished 2018
Nimotuzumab in the Management of Carcinoma of Cervix: A Case Report
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Survival is poor with conventional treatment especially in patients with advanced cervical cancer. In this case report, a 51-years-old patient of cervical cancer with large cervical mass invading the uterine body and left terminal ureter was treated with neoadjuvant chemoradiotherapy followed by concurrent chemoradiotherapy. Weekly Nimotuzumab 200 mg was administered during neoadjuvant chemotherapy as well as concurrent chemoradiotherapy. At the end of the treatment patient showed no evidence of disease. Disease recurred after one and half years and patient was treated with weekly nab-paclitaxel along with the Nimotuzumab for 16 weeks. Patient had no evidence of disease and is healthy, comfortably doing daily activities after 4 years of treatment. Use of Nimotuzumab in this patient of cervical cancer was safe and showed excellent outcomes.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalGynecology & Obstetrics Case report
- SubjectReproductive Medicine & Gynaecology
- BylineArticles whose byline prints “Shyamji Rawat”